BACKGROUND: Clinicopathologic features, treatment, and results are reported for 95 tendosynovial sarcomas identified from a prospective sarcoma data base established at Memorial Sloan-Kettering Cancer Center (MSKCC) in 1982. METHODS: Eighty-five patients had definitive treatment of the primary tumor at MSKCC: Epithelial sarcomas were excluded. RESULTS: The local recurrence rate was 18%. Survival rates were not influenced by either the method of local treatment or the use of chemotherapy. The overall actuarial survival rate was 59% at 5 years (median, 92 months). For 25 patients who had resection of pulmonary metastases, the 5-year actuarial survival rate was 43% (median, 22 months) from the time of first thoracotomy. Sex, age, tumor site, and histologic subtype (monophasic versus biphasic) were not significant predictors of survival rates. Regional lymph node metastasis occurred in 3%. The incidence of distant metastasis was 49%, with an associated 5-year survival rate of 31% (median, 33 months). Tumor size was a highly significant prognostic feature, with 5-year survival rates of 86% for patients with tumors smaller than 5 cm and 22% for those with tumors larger than 10 cm (P less than 0.00001). CONCLUSIONS: Improvement of treatment results for tendosynovial sarcoma will require effective new systemic adjuvant therapeutic strategies.
BACKGROUND: Clinicopathologic features, treatment, and results are reported for 95 tendosynovial sarcomas identified from a prospective sarcoma data base established at Memorial Sloan-Kettering Cancer Center (MSKCC) in 1982. METHODS: Eighty-five patients had definitive treatment of the primary tumor at MSKCC: Epithelial sarcomas were excluded. RESULTS: The local recurrence rate was 18%. Survival rates were not influenced by either the method of local treatment or the use of chemotherapy. The overall actuarial survival rate was 59% at 5 years (median, 92 months). For 25 patients who had resection of pulmonary metastases, the 5-year actuarial survival rate was 43% (median, 22 months) from the time of first thoracotomy. Sex, age, tumor site, and histologic subtype (monophasic versus biphasic) were not significant predictors of survival rates. Regional lymph node metastasis occurred in 3%. The incidence of distant metastasis was 49%, with an associated 5-year survival rate of 31% (median, 33 months). Tumor size was a highly significant prognostic feature, with 5-year survival rates of 86% for patients with tumors smaller than 5 cm and 22% for those with tumors larger than 10 cm (P less than 0.00001). CONCLUSIONS: Improvement of treatment results for tendosynovial sarcoma will require effective new systemic adjuvant therapeutic strategies.
Authors: Bernd W Scheithauer; Ana Isabel Silva; Keith Kattner; Jason Seibly; Andre M Oliveira; Kalman Kovacs Journal: Neuro Oncol Date: 2007-08-17 Impact factor: 12.300
Authors: Zsófia Balogh; Zsuzsanna Szemlaky; Miklós Szendroi; Imre Antal; Zsuzsanna Pápai; László Fónyad; Gergo Papp; Yi C Changchien; Zoltán Sápi Journal: Diagn Pathol Date: 2011-11-03 Impact factor: 2.644
Authors: A Mezzelani; L Mariani; E Tamborini; V Agus; C Riva; S Lo Vullo; A Fabbri; M Stumbo; A Azzarelli; P G Casali; A Gronchi; G Sozzi; M A Pierotti; S Pilotti Journal: Br J Cancer Date: 2001-11-16 Impact factor: 7.640
Authors: Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel Journal: J Cancer Res Clin Oncol Date: 2021-07-17 Impact factor: 4.553